Trump Tariffs Deter US Investment

Introduction to Pfizer’s Investment Plans

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S.

Impact of Tariffs on Investment Decisions

Bourla stated that the uncertainty surrounding tariffs is a significant factor in the company’s investment decisions. "If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing," Bourla said on the call, adding that the company is also hoping for "certainty." He noted that in periods of uncertainty, the company is controlling its costs and being frugal with investments to prepare for potential risks.

Tax Environment and Investment Incentives

Bourla noted that the tax environment, which had previously pushed manufacturing abroad, has "significantly changed now" with the establishment of a global minimum tax of around 15%. However, he said that this shift hasn’t necessarily made the U.S. more attractive, saying "it’s not as good" to invest here without additional incentives or clarity around tariffs. He added that a further decrease in taxes would be a strong incentive for manufacturing in the U.S.

Guidance and Tariff-Related Costs

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance "does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time." On the earnings call, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

Conclusion

In conclusion, Pfizer’s investment plans in the U.S. are being deterred by the uncertainty surrounding President Trump’s planned pharmaceutical tariffs. The company is seeking clarity and certainty around tariffs to make informed investment decisions. A decrease in taxes and additional incentives could make the U.S. a more attractive location for investment.

FAQs

Q: What is deterring Pfizer from investing in U.S. manufacturing and research and development?

A: The uncertainty surrounding President Donald Trump’s planned pharmaceutical tariffs is deterring Pfizer from further investing in U.S. manufacturing and research and development.

Q: What is Pfizer seeking from tariff negotiations?

A: Pfizer is seeking clarity and certainty around tariffs to make informed investment decisions.

Q: How has the tax environment changed?

A: The tax environment has significantly changed with the establishment of a global minimum tax of around 15%.

Q: What would make the U.S. a more attractive location for investment?

A: A decrease in taxes and additional incentives would make the U.S. a more attractive location for investment.

Q: How much in costs from Trump’s existing tariffs is reflected in Pfizer’s guidance?

A: $150 million in costs from Trump’s existing tariffs is reflected in Pfizer’s guidance.